EXPE vs PCVX · P/E 20, rev $13.69B vs $6.84B cap
Expedia Group Inc. (EXPE) versus Vaxcyte Inc (PCVX) — a side-by-side from cached financials, not a winner call.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
Vaxcyte Inc (PCVX) is a biotechnology company listed on US.
Latest reported EXPE revenue for 2024-12-31 was $13.69B. Net income was $1.22B. Revenue was up 6.6% from 2023-12-31 to 2024-12-31. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
PCVX does not have a complete income-statement cache yet.
EXPE currently screens at market cap $21.71B and trailing P/E 20.4. PCVX currently screens at market cap $6.84B.
Not investment advice. Open the EXPE and PCVX stock pages for the full models.
Not investment advice.